^
    2d
    A11 Peptide Enhances Radiosensitivity by Degrading EphA2 in Nasopharyngeal Carcinoma. (PubMed, Cancer Sci)
    These findings indicate that EphA2 overexpression and its S897 phosphorylation play a critical role in NPC radioresistance. The A11 peptide emerges as a promising therapeutic agent by degrading EphA2 and blocking its phosphorylation, offering a potential strategy to enhance radiotherapy efficacy and improve outcomes in NPC patients.
    Journal
    |
    EPHA2 (EPH receptor A2)
    2d
    Aberrant lipid metabolism reshapes the immune landscape in bone metastasis of nasopharyngeal carcinoma. (PubMed, J Immunother Cancer)
    The synergy between the SPHK1 inhibitor PF543 and anti-programmed cell death protein 1 therapy amplified treatment effectiveness beyond standalone approaches. Overall, the SPHK1/S1P pathway advances NPC growth and aids in suppressing immune defense. Regulation of lipid metabolism may be a therapeutic target against BM in NPC and may improve the effectiveness of immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8) • SPHK1 (Sphingosine Kinase 1)
    3d
    PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Guangxi Medical University | Trial completion date: Mar 2026 --> Mar 2029
    Trial completion date
    |
    cisplatin
    3d
    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Keytruda (pembrolizumab) • VMD-928
    3d
    Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=60, Completed, Guangxi Medical University | Unknown status --> Completed | Trial completion date: Jun 2022 --> Oct 2025
    Trial completion • Trial completion date
    |
    cisplatin • 5-fluorouracil • albumin-bound paclitaxel
    3d
    REDEFINE: Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II) (clinicaltrials.gov)
    P2, N=23, Recruiting, Jiangxi Provincial Cancer Hospital
    New P2 trial
    3d
    Anti-LAG-3 Antibody LBL-007 Plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial. (PubMed, Clin Cancer Res)
    LBL-007 plus tislelizumab and chemotherapy shows promising clinical benefits and manageable toxicity as first-line therapy for RM-NPC. Dual-positive LAG-3/PD-L1 expression was associated with improved outcomes, supporting further exploration of this biomarker-defined subpopulation in randomized trials.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007)
    3d
    Targeting Ferroptosis in Nasopharyngeal Carcinoma: Mechanisms, Resistance, and Precision Therapeutic Opportunities. (PubMed, Int J Mol Sci)
    Future directions include biomarker validation, optimization of drug delivery, early-phase clinical trial development, and multidisciplinary collaboration to balance ferroptosis induction in tumors while protecting normal tissues. Collectively, ferroptosis is emerging as both a vulnerability and a therapeutic opportunity for improving outcomes in NPC.
    Review • Journal • IO biomarker
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • HOXA9 (Homeobox A9) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL3 (Methyltransferase Like 3)
    4d
    YTHDF2 enhances proliferation and metastasis of nasopharyngeal carcinoma by mediating m6A modification in destabilizing FOXO1 mRNA. (PubMed, Cancer Biol Ther)
    YTHDF2 potentially functions as an oncogene in NPC by binding to the m6A site of FOXO1, reducing its expression, thereby promoting malignant behavior. It may also be a viable biomarker and therapeutic target for NPC.
    Journal
    |
    FOXO1 (Forkhead box O1) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    6d
    Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=474, Not yet recruiting, Fujian Cancer Hospital
    New P3 trial • Head-to-Head
    6d
    circSETD3 confers radiotherapy resistance in nasopharyngeal carcinoma by attenuating ER stress-induced autophagy and apoptosis via PDIA6 upregulation. (PubMed, Oncogene)
    This alleviation of ER stress reduces radiation-induced autophagy and apoptosis, ultimately enhancing NPC cell survival under radiotherapeutic stress. Together, these findings reveal a pivotal role for circSETD3 in promoting NPC radioresistance via PDIA6-mediated modulation of endoplasmic reticulum stress, and they provide a novel mechanistic framework and promising therapeutic target for improving radiotherapy efficacy in NPC.
    Journal
    |
    PDIA6 (Protein Disulfide Isomerase Family A Member 6) • SETD3 (SET Domain Containing 3)
    6d
    Trop2-targeted immunoPET Imaging of Solid Tumors (clinicaltrials.gov)
    P2/3, N=400, Recruiting, RenJi Hospital | Phase classification: P=N/A --> P2/3
    Phase classification